Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.67
+1.1%
$3.09
$2.46
$4.15
$320.07M0.25323,610 shs286,948 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$13.14
+3.1%
$14.27
$7.05
$17.15
$345.71M0.3755,949 shs74,946 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$8.03
-0.1%
$7.05
$3.68
$8.63
$297.68M0.71228,540 shs55,721 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.25
+3.8%
$1.40
$1.10
$16.10
$77.35M1.31.19 million shs1.12 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+6.38%+15.05%+31.54%+11.89%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.00%+15.77%-13.38%+6.66%+48.64%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
0.00%-1.95%+18.96%+51.80%+62.88%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
0.00%-0.40%-22.67%-7.09%-88.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.3589 of 5 stars
3.32.00.00.00.62.51.3
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.0198 of 5 stars
3.62.00.00.02.50.80.0
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
1.0157 of 5 stars
1.32.00.00.01.14.20.6
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
3.9888 of 5 stars
3.04.00.04.70.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0063.49% Upside
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.22
Buy$23.8381.38% Upside
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.50
Moderate Buy$8.00-0.37% Downside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31969.28% Upside

Current Analyst Ratings Breakdown

Latest PLRX, LFCR, BNTC, and AVIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/19/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/11/2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00
4/10/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$5.20 per shareN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$4.68 per shareN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.26M2.32N/AN/A$0.37 per share21.70
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M48.37N/AN/A$5.00 per share0.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$12.01M-$1.45N/AN/AN/A-35.90%-551.09%-13.89%8/15/2025 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)

Latest PLRX, LFCR, BNTC, and AVIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.36-$0.24+$0.12-$0.24N/AN/A
5/12/2025Q1 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.56-$0.40+$0.16-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.94
19.94
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
66.36
2.71
1.59
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
11.03
11.03

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.30%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.20%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7085.58 million70.09 millionOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
69037.03 million25.10 millionOptionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.48 millionOptionable

Recent News About These Companies

Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics announces workforce reduction

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.67 +0.04 (+1.10%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$3.65 -0.02 (-0.54%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$13.14 +0.40 (+3.14%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$8.03 -0.01 (-0.12%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.25 +0.05 (+3.75%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$1.25 0.00 (0.00%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.